CIK 0000944809 · Accelerated filer
OPKO HEALTH, INC.
Sign in to watch- Ticker
- OPK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 752402409
- Phone
- 305-575-4181
- Business address
- 4400 BISCAYNE BLVD., MIAMI, FL, 33137
- Former names
- EXEGENICS INC, eXegenics Inc, CYTOCLONAL PHARMACEUTICS INC /DE
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $24,577
- in 1 filing
Net −$24,577. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-18 | FROST PHILLIP MD ET AL CEO & Chairman | Purchase | +69,728 | $1.28 | $89K | 214,848,891 |
| 2025-11-18 | FROST PHILLIP MD ET AL CEO & Chairman | Purchase | +428 | $1.28 | $550 | 214,849,319 |
| 2025-11-18 | FROST PHILLIP MD ET AL CEO & Chairman | Purchase | +83,556 | $1.29 | $107K | 214,932,875 |
| 2025-11-18 | FROST PHILLIP MD ET AL CEO & Chairman | Purchase | +1 | $1.29 | $1 | 214,932,876 |
| 2025-11-18 | FROST PHILLIP MD ET AL CEO & Chairman | Purchase | +33,572 | $1.29 | $43K | 214,966,448 |
| 2025-10-31 | FROST PHILLIP MD ET AL CEO & Chairman | Purchase | +150,000 | $1.42 | $213K | 214,386,448 |
| 2025-08-18 | FROST PHILLIP MD ET AL CEO & Chairman | Gift | −440,000 | 214,236,448 | ||
| 2025-08-08 | FROST PHILLIP MD ET AL CEO & Chairman | Purchase | +675,000 | $1.32 | $891K | 214,676,448 |
| 2025-05-27 | FROST PHILLIP MD ET AL CEO & Chairman | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 | ||
| 2025-05-27 | HSIAO JANE PH D Vice Chairman & CTO | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 | ||
| 2025-05-27 | Zerhouni Elias A. Vice Chairman and President | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 | ||
| 2025-05-27 | Rubin Steven D Executive VP-Administration | Grant or award · Stock Option (Right to Buy) | +437,500 | 437,500 | ||
| 2025-05-27 | Logal Adam Sr. Vice President, CFO | Grant or award · Stock Option (Right to Buy) | +437,500 | 437,500 | ||
| 2025-05-27 | Nabel Gary J. Chief Innovation Officer | Grant or award · Stock Option (Right to Buy) | +437,500 | 437,500 | ||
| 2025-04-23 | KRASNO RICHARD M Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2025-04-23 | Lachman Prem A Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2025-04-23 | MEDEL ROGER MD Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2025-04-23 | PAGANELLI JOHN A Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2025-04-23 | PFENNIGER RICHARD C JR Director | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2025-04-23 | Yu Alice Lin-Tsing Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 |
Page 3 of 8 · 159 trades